Physician

Joseph Derit Te, M.D.

According to 2025 Medicare claims, Joseph Te, M.D. (NPI: 1700946423) practices hematology/oncology in the St. George, UT market, with the plurality of this provider's patient population coming from Washington, UT. This provider's primary affiliated billing organization is REVERE HEALTH PC (NPI: 1093764805; TIN: 870281028) and primary practice location at 84790-9998. Te is affiliated with the Revere Health Collaborative Network, LLC (ACO ID: D0042), participating under the REACH model.

Te's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,189 traditional Medicare patients, billed 286,896 HCPCS/CPT codes, and received $4,393,872 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 1,592 prescription claims across 294 beneficiaries totaling $8,444,663 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 48 claims. Open Payments data shows 208 records totaling $5,030. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,027,049 to $8,444,663. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $25,335 to $2,340.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,153	232,810	$3,303,872
2016	1,158	196,647	$4,047,451
2017	1,146	253,375	$4,512,595
2018	1,230	265,340	$4,465,164
2019	1,227	325,455	$5,726,527
2020	1,258	283,142	$5,723,766
2021	1,181	268,154	$5,323,045
2022	1,126	327,439	$4,559,099
2023	1,190	271,092	$4,526,867
2024	1,189	286,896	$4,393,872

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	301	1,522	$2,027,049
2016	310	1,747	$3,376,821
2017	286	1,327	$2,414,796
2018	258	1,445	$2,831,131
2019	278	1,171	$3,110,263
2020	265	1,261	$5,452,485
2021	260	1,137	$5,975,256
2022	255	1,153	$6,744,839
2023	283	1,341	$6,904,460
2024	294	1,592	$8,444,663

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	25	313	$57,009
2016	N/R	207	$36,337
2017	14	57	$4,385
2018	30	57	$8,466
2019	N/R	34	$4,306
2020	N/R	13	$1,708
2021	N/R	70	$35,049
2022	N/R	41	$1,514
2023	N/R	46	$82,309
2024	N/R	48	$1,395

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	650	918	$60
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	898	1,823	$11
80053	Blood test, comprehensive group of blood chemicals	696	1,370	$10
36415	Insertion of needle into vein for collection of blood sample	720	2,022	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	748	2,489	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	123	3,472	$2,001,599
Calquence	Acalabrutinib Maleate	71	2,130	$1,050,932
Revlimid	Lenalidomide	40	994	$669,491
Lenalidomide	Lenalidomide	44	1,211	$628,014
Abiraterone Acetate	Abiraterone Acetate	183	5,490	$493,780

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	23	$1,006
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$163

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	208	$5,030	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joseph Derit Te, M.D.?

Tedicare shows public-source Medicare data for Joseph Derit Te, M.D. (NPI 1700946423), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joseph Derit Te, M.D. have ACO affiliation data?

Joseph Derit Te, M.D. is shown with ACO affiliation data for Revere Health Collaborative Network, LLC (REACH, ACO ID D0042).

What billing organization is linked to Joseph Derit Te, M.D.?

Joseph Derit Te, M.D. is linked to REVERE HEALTH PC (billing NPI 1093764805) in the available physician profile data.

Does Joseph Derit Te, M.D. have Open Payments data?

Joseph Derit Te, M.D. has 208 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.